## **Core Concept**
The question pertains to the prenatal treatment of Congenital Adrenal Hyperplasia (CAH), a group of inherited disorders that affect the adrenal glands, leading to an imbalance in the production of steroid hormones. The most common cause of CAH is 21-hydroxylase deficiency, which results in decreased production of cortisol and aldosterone and an overproduction of androgens.

## **Why the Correct Answer is Right**
The correct answer, **Dexamethasone**, is a synthetic glucocorticoid that can cross the placenta and suppress fetal adrenal androgen production, thereby preventing virilization in female fetuses affected by CAH. Administering dexamethasone to mothers at risk of having a child with CAH can prevent or reduce the severity of virilization in female fetuses. This treatment is considered when there is a known family history of CAH and after confirming the risk through genetic testing.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is blank and does not provide a valid choice for consideration.
- **Option B:** This option is also blank and does not offer a viable treatment option for CAH.
- **Option C:** Similarly, this option is blank and lacks relevance to the treatment of CAH.

## **Clinical Pearl / High-Yield Fact**
A critical point to remember is that prenatal treatment with dexamethasone is only offered to mothers who are at high risk of having a child with CAH (e.g., a previous child with CAH or a known genetic risk). The treatment must be initiated early in pregnancy, ideally before the 9th week, to be effective. Additionally, because the treatment is not without risks, it is usually recommended to confirm the fetal sex and genotype before continuing with the treatment.

## **Correct Answer:** D. Dexamethasone